Smmary To improve the efficiency of hepatic intra-arterial (h.i.a.) chemotherapy, we selected pirarubicin (THP) because it shows good properties for h.i.a. chemotherapy, such as fast and efficient cellular uptake, and used it for h.i.a. chemotherapy in rabbits with V x 2 tumour implanted in the liver. The anti-tumour effect of THP upon h.i.a. administration was compared with that upon intravenous (i.v.) injection and also with the anti-tumour activity of epirubicin (EPI) upon h.i.a. injection using optimal and maximal tolerated doses of each drug. When tumour growth rates and morphometric examinations were evaluated, it was found that THP and EPI were effective against V x 2 tumour when injected via the h.i.a. route. The activity of THP was stronger than that of EPI. As regards h.i.a. injection-related complications, plasma transaminase levels were temporarily elevated. To demonstrate higher anti-tumour activity and other advantages of h.i.a. injection of THP. plasma and tumour drug concentrations were determined by high-performance liquid chromatography after THP or EPI was administered at an equal dose to the rabbit V x 2 model. Hepatic intra-arterial injection of THP accomplished a selective and higher uptake into the tumour and lower effusion into the plasma than i.v. injection of THP or h.i.a. injection of EPI. Our findings indicate that THP is the better candidate of the two drugs tested for the h.i.a. chemotherapy because of its greater anti-tumour activity and the lower systemic drug exposure achieved upon h.i.a. injection.
Primary hepatocellular carcinoma (HCC) is usually considered a highly malignant tumour with a prognosis of a few months' survival from the time of diagnosis (Nagasue et al., 1984) . The best current treatment of HCC is surgical removal of the primary tumour, but this is successful in only 10-20% of patients (Okuda et al., 1980 (Okuda et al., , 1985 because of the highly malignant nature of the tumour and its frequent association with cirrhosis. Thus, for patients with non-resectable HCC, hepatic intra-arterial (h.i.a.) chemotherapy has been widely used in attempts to improve the response rate and the survival.
The rationale for h.i.a. chemotherapy is based upon the fact that liver tumours, either primary or metastatic, are mainly nourished by the hepatic artery (Ackerman, 1972; Ridge et al., 1987) . Hence, chemotherapeutic agents injected directly into the hepatic artery can be more effective than those administered by the systemic route by increasing the exposure of the tumour to a drug.
Among various anti-tumour drugs, doxorubicin (DOX) is one of the most effective cytotoxic agents in the treatment of HCC and has also been frequently used in h.i.a. chemotherapy. However, h.i.a. chemotherapy with DOX does not seem to show any clear advantage over systemic administration because, although the response rate is slightly increased and the median survival time appears to be somewhat increased no reduction in systemic toxicity is observed when this route is used (Shah et al., 1977; Bern et al., 1978; Garnick et al., 1979) .
A crucial element in successful h.i.a. chemotherapy is the use of appropriate drugs. Pirarubicin (THP), a novel DOX analogue with lower cardiotoxicity, is efficiently metabolised by the liver in a similar way to other anthracycline agents and the drug plasma clearance is more than 1.5-fold higher than that of DOX (Iguchi et al., 1985) . Furthermore, the cellular uptake of THP is faster and more effective than that of DOX (Kunimoto et al., 1983) . Hence, we speculated that THP is a good candidate for h.i.a. chemotherapy.
In the present study, to prove the hypothesis, we administered THP by h.i.a. injection at the maximal tolerated dose (MTD) or the optimal dose (half of MTD) in rabbits with a V x 2 tumour implanted in the liver. The anti-tumour activity of THP was then compared with that obtained by intravenous (i.v.) injection and with that of epirubicin (EPI) administered by h.i.a. injection, since the clinical evaluation of EPI through h.i.a. injection has been performed and is indicated (Pannuti et al.. 1986; Ando, 1987) . In the evaluation of anti-tumour activity, morphometric examinations were performed for quantitative evaluations using a colour image analyser on tumour cross-sections. We also determined drug concentrations in the plasma and the tumour after injection of THP and EPI via the i.v. or h.i.a. route and assessed the pharmacokinetic advantage of THP injection via the h.i.a. route.
Materias and methods

Chemicals
Pirarubicin (THP) was provided by Mercian (Tokyo, Japan). Epirubicin (EPI) was purchased from Kyowa Hakko Kogyo (Tokyo, Japan). These drugs were dissolved in distilled water as stock solutions, and they were diluted again by 4.5% sodium chloride solution (final concentration of 0.9% sodium chloride) to obtain the required concentrations of the drugs for injection.
Animals
Female Japanese White rabbits weighing 2-3 kg were purchased from Kitayama Labes (Kyoto, Japan For pathological examination, liver slices through the centre of the tumour were stained with haematoxylin and eosin (H&E) and examined with a microscope. Morphometric examinations were also performed using a colour image analyser (Luzexs-III; Nireco, Tokyo, Japan) on the H&E-stained cross-sections to evaluate quantitatively the histological-anti-tumour effect. In morphometric evaluations, the haematoxylin-coloured viable cells were automatically collected from each tumour mass. Then, the ratio of the area of viable tumour cells to the area of tumour mass was calculated and presented for each group. In addition, three fields of 400 x magnification were randomly selected from the outer rim of the tumour in cross-sections after treatment with THP or EPI at the MTD, and examined for the measurement of tumour nuclear size (pnm). Tumour nuclear sizes were measured and input into a colour image analyser, and the distribution pattern in each group was demonstrated as the necrotic index.
Measrements ofplawna GOT, GPT and T-BIL levels Plasma GOT, GPT and T-BIL levels were measured by a biochemical autoanalyser (Hitachi, 750, Hitachi Koki, Tokyo, Japan) to evaluate hepatic and biliary toxicities due to drug exposure.
Animal study for determination ofplasma and tissue drug levels
In a separate experiment, 10 or 11 days after tumour implantation, three rabbits in each group received an i.v. injection of h.i.a. injection of 2.2 mg kg-' THP or EPI under general anaesthesia. Blood samples were collec from animals in all Figure 2 ), except in the group given 3.1 mg kg-' EPI ( Figure 2 and Table II ). In the group given h.i.a. THP, necrosis of entire tumours was observed and the necrosis was massive (Figures lb and 2 ). Thus, of all the treatments tested, THP administered by h.i.a. injection showed the strongest anti-tumour activity against this tumour system.
Hepatic and biliary toxicity after treatment
Figures 4 and 5 show the plasma GOT and T-BIL levels before and after each treatment. In some groups given h.i.a.
injections of THP and EPI, plasma GOT levels were temporarily and statistically significantly elevated on day 3 after injection but fell to levels close to normal levels on day 7. Plasma GPT levels changed in the same manner as the GOT levels in these groups (data not shown). No differences were observed between the THP and EPI groups. Plasma T-BIL levels did not change appreciably in any of the groups.
Drug levels in plasma and twnour after treatment Plasma drug levels during a 2 h period after i.v. or h.i.a. injection of 2.2 mg kg-' THP or EPI are shown in Figure 6 . Plasma levels of THP and EPI after h.i.a. injection were consistently lower than those after i.v. injection at all times. The difference in plasma levels after i.v. and h.i.a. injections was distinctly greater for THP than for EPI. The maximal concentrations (C..) in plasma accounted for the difference (Table III Similarlv. the AUC of EPI upon h.i.a. injection w-as 2.3-fold smaller than that upon ix. injection. The plasma AUC and C__ for THP Miven via h.i.a. injection w-ere remarkabl-low-er than those of other treatments (Table 111T . The plasma disappearance and tissue transfer of THP and EPI upon h.i.a. iniection w-ere faster than those upon i.x-injection (Table  111) . Drug levels in V x 2 tumour and normal liver tisse 2 h after i.x. or h.i.a. iniection of THP or EPI are shou-n in Table IV . In the tumour the mean level of THP after h.i.a. iniection w-as about IS-fold higher than that after iLx. injection. In the case of h.i.a. injection the THP level in the tumour wxas about 5-and 90-fold higher than that of the proximal normal lixer tissue and of distal normal rinht lixver tissue respectivelv. The mean lexel of EPI after h.i.a. injection was about 25-fold hiTher than that after ix. iniection. though in one of the three amnmals EPI w-as undetectable. Therefore. w-e antici- pated that this compound w-ould also be a good candidate for successful h.i.a. chemotherapx.
In the present study. w-e compared the anti-tumour actixities and pharmacokinetics of THP and EPI after i.x-. or h.i.a. injection in the rabbit V x model. This model u-as selected because of the similan'tv of its xascularisation to human liver metastases and primar-tumours (Breedis and Y-ounz. 1954: Miller et al.. 198-s The efficacy of h.i.a. chemotherapy has been frequently limited by drugs' hepatic and biliary toxicity (Hohn et al., 1986) . Plasma GOT and GPT levels, which are considered to be markers for the disturbance of hepatic cells, were significantly elevated 3 days after h.i.a. injection with either of the drugs used and fell to near-baseline levels within 7 days. However, elevation of these markers was not observed when these drugs were administered by i.v. injection. These results suggest that THP and EPI were cytotoxic in normal hepatic cells when they were directly injected via the hepatic artery but that the disturbances were reversible. Plasma T- BIL levels, a marker of biliary toxicity, were not elevated in any treatments.
The pharmacokinetic data on THP and EPI after i.v. or h.i.a. injection confirmed the potential advantage of h.i.a. injection with THP. The h.i.a. injection of THP would result in a lower exposure of healthy tissues of other organs to the drug, since the AUC measured in systemic plasma was markedly reduced following treatment compared with that upon i.v. injection of the drug. Moreover, h.i.a. injection of THP achieved higher intratumoral drug concentrations. When THP was compared with EPI, the intratumoral accumulation of THP after h.i.a. injection was about 2-fold higher than that of EPI after the same procedure. The results of these studies revealed that the increase in tumour THP concentration after h.i.a. as compared with i.v. injection was higher than those of other drugs tested, i.e. cisplatin and doxorubicin, in the rabbit V x 2 model (Khokhar et al., 1988; Ridge et al., 1988) . Furthermore, h.i.a. injection with THP resulted in selective drug accumulation in the tumour, since the THP level was about 90-fold higher than that in the normal liver tissues of non-tumour-bearing lobe. Hepatic intra-arterial injection of EPI was also observed to result in selective accumulation, but the selectivity was inferior to that obtained upon h.i.a. injection of THP.
Our observations in this study clearly demonstrate the superiority of h.i.a. injection of THP compared with i.v. injection of THP and h.i.a. injection of EPI with regard to the therapeutic efficacy and pharmacokinetic behaviour. Therefore, we believe that THP is a better candidate than other drugs, including EPI, for h.i.a. chemotherapy in the treatment of HCC and metastatic liver cancer. Treatment with THP via h.i.a. injection is now in the late stage of a phase II study in Japan.
